Man Group
CBIO

Man Group’s Crescent Biopharma CBIO Stock Holding History

Man Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,499
Closed -$450K – 2109
2024
Q1 		$450K Buy
+1,499
New +$448K ﹤0.01% 1816
2022
Q4 		– Sell
-176
Closed -$10K – 2071
2022
Q3 		$10K Buy
+176
New +$12.6K ﹤0.01% 1981
2021
Q2 		– Sell
-279
Closed -$84K – 2003
2021
Q1 		$84K Sell
279
-292
-51% -$105K ﹤0.01% 1804
2020
Q4 		$215K Buy
+571
New +$200K ﹤0.01% 1724
2019
Q3 		– Sell
-4,955
Closed -$5.91M – 1832
2019
Q2 		$5.91M Sell
4,955
-510
-9% -$610K 0.02% 879
2019
Q1 		$6.81M Sell
5,465
-489
-8% -$560K 0.03% 752
2018
Q4 		$5.64M Buy
5,954
+1,834
+45% +$2.21M 0.03% 717
2018
Q3 		$5.93M Buy
4,120
+3,553
+627% +$5.37M 0.02% 895
2018
Q2 		$914K Buy
+567
New +$975K ﹤0.01% 1628

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return